Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Barry S. Rodgers-Gray, John R. Fullarton, Xavier Carbonell-Estrany, Ian P. Keary, Jean-Éric Tarride & Bosco A. Paes. (2023) Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics 26:1, pages 630-643.
Read now
Read now
Robert Cox & Richard K. Plemper. (2016) Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opinion on Drug Discovery 11:6, pages 543-556.
Read now
Read now
Haben Y Abraha, Krista L Lanctôt & Bosco Paes. (2015) Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine 9:6, pages 779-799.
Read now
Read now
Articles from other publishers (29)
Ian P. Keary, Roberto Ravasio, John R. Fullarton, Paolo Manzoni, Marcello Lanari, Bosco A. Paes, Xavier Carbonell-Estrany, Eugenio Baraldi, Jean-Éric Tarride & Barry Rodgers-Gray. (2023) A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLOS ONE 18:8, pages e0289828.
Crossref
Crossref
Mary T. Caserta, Sean T. O’Leary, Flor M. Munoz, Shawn L. Ralston, Sean T. O’Leary, James D. Campbell, Monica I. Ardura, Ritu Banerjee, Kristina A. Bryant, Mary T. Caserta, Jeffrey S. Gerber, Chandy C. John, Athena P. Kourtis, Angela Myers, Pia Pannaraj, Adam J. Ratner, José R. Romero, Samir S. Shah, Kenneth M. Zangwill, Yvonne A. Maldonado, Flor M. Munoz, Shawn L. Ralston, David W. Kimberlin, Elizabeth D. Barnett, Ruth Lynfield, Mark H. Sawyer, Henry H. Bernstein, Karen M. Farizo, Lisa M. Kafer, David Kim, Eduardo López Medina, Denee Moore, Lakshmi Panagiotakopoulos, Laura Sauvé, Jeffrey R. Starke, Jennifer Thompson, Kay M. Tomashek, Melinda Wharton, Charles R. WoodsJr.Jr. & Jennifer M. Frantz. (2023) Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics.
Crossref
Crossref
Dhwani Hariharan, V. S. Senthil Kumar, Elizabeth L Glaser, William H. Crown, Zachary A. Wolf, Kimberley A. Fisher, Charles T. Wood, William F. Malcolm, Christopher B. Nelson & Donald S. Shepard. (2023) Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing: Pilot prospective observational study. Health Science Reports 6:6.
Crossref
Crossref
Michela Servadio, Valeria Belleudi, Federco Marchetti & Antonio Addis. (2022) La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab. Medico e Bambino 41:10, pages 632-639.
Crossref
Crossref
Elizabeth L Glaser, Dhwani Hariharan, Diana M Bowser, Raíssa M Gervasio, Katharine R Rowlands, Lauren Buckley, Christopher B Nelson & Donald S Shepard. (2022) Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis. The Journal of Infectious Diseases 226:Supplement_2, pages S236-S245.
Crossref
Crossref
C.E. Rodriguez-Martinez, M.P. Sossa-Briceño & J.A. Castro-Rodriguez. (2020) Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergologia et Immunopathologia 48:1, pages 56-61.
Crossref
Crossref
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Crossref
Gary M. Ginsberg, Eli Somekh & Yechiel Schlesinger. (2018) Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis. Israel Journal of Health Policy Research 7:1.
Crossref
Crossref
Jeong-Joong Yoon, Mart Toots, Sujin Lee, Myung-Eun Lee, Barbara Ludeke, Jasmina M. Luczo, Ketaki Ganti, Robert M. Cox, Zachary M. Sticher, Vindya Edpuganti, Deborah G. Mitchell, Mark A. Lockwood, Alexander A. Kolykhalov, Alexander L. Greninger, Martin L. Moore, George R. Painter, Anice C. Lowen, Stephen M. Tompkins, Rachel Fearns, Michael G. Natchus & Richard K. Plemper. (2018) Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrobial Agents and Chemotherapy 62:8.
Crossref
Crossref
Natalia Olchanski, Ryan N Hansen, Elle Pope, Brittany D’Cruz, Jaime Fergie, Mitchell Goldstein, Leonard R Krilov, Kimmie K McLaurin, Barbara Nabrit-Stephens, Gerald Oster, Kenneth Schaecher, Fadia T Shaya, Peter J Neumann & Sean D Sullivan. (2018) Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infectious Diseases 5:3.
Crossref
Crossref
Ahva Shahabi, Desi Peneva, Devin Incerti, Kimmie McLaurin & Warren Stevens. (2017) Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants. PharmacoEconomics - Open 2:1, pages 53-61.
Crossref
Crossref
Ralph Schmidt, Istvan Majer, Natalia García Román, Alejandra Rivas Basterra, ElizaBeth Grubb & Constancio Medrano López. (2017) Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Economics Review 7:1.
Crossref
Crossref
M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres & X. Carbonell-Estrany. (2017) Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infectious Diseases 17:1.
Crossref
Crossref
Heather E. Hoch & Joseph M. Collaco. (2017) Recurrent Wheezing in Childhood and Palivizumab. American Journal of Respiratory and Critical Care Medicine 196:1, pages 1-2.
Crossref
Crossref
Abby Li, Daniel Y. Wang, Krista L. Lanctôt, Ian Mitchell & Bosco A. Paes. (2017) Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015). Pediatric Infectious Disease Journal 36:5, pages 445-450.
Crossref
Crossref
Bavani Rajah, Pablo J. Sánchez, Cristina Garcia-Maurino, Amy Leber, Octavio Ramilo & Asuncion Mejias. (2017) Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience. The Journal of Pediatrics 181, pages 183-188.e1.
Crossref
Crossref
Carlina J. Grindeland, Clifford T. Mauriello, David D. Leedahl, Lisa M. Richter & Anne C. Meyer. (2016) Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. Pediatric Infectious Disease Journal 35:7, pages 728-732.
Crossref
Crossref
Arielle Olicker, Hong Li, Curtis Tatsuoka, Kristie Ross, Andrea Trembath & Anna Maria Hibbs. (2016) Have Changing Palivizumab Administration Policies Led to More Respiratory Morbidity in Infants Born at 32-35 Weeks?. The Journal of Pediatrics 171, pages 31-37.
Crossref
Crossref
Bernhard Resch, Stefan Kurath-Koller, Monika Eibisberger & Werner Zenz. (2015) Prematurity and the burden of influenza and respiratory syncytial virus disease. World Journal of Pediatrics 12:1, pages 8-18.
Crossref
Crossref
Dan Yan, Marco Weisshaar, Kristen Lamb, Hokyung K. Chung, Michael Z. Lin & Richard K. Plemper. (2015) Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Biochemistry 54:36, pages 5589-5604.
Crossref
Crossref
Daniel M. Weinberger, Joshua L. Warren, Claudia A. Steiner, Vivek Charu, Cécile Viboud & Virginia E. Pitzer. (2015) Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus. Clinical Infectious Diseases 61:4, pages 506-514.
Crossref
Crossref
Marco WeisshaarRobert CoxRichard K. Plemper. (2015) Blocking Respiratory Syncytial Virus Entry: A Story with Twists. DNA and Cell Biology 34:8, pages 505-510.
Crossref
Crossref
Israel Matías, Inés García-García, Lourdes García-Fragoso & Marta Valcárcel. (2014) Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season. Journal of Community Health 39:6, pages 1040-1044.
Crossref
Crossref
Michael T. Brady, Carrie L. Byington, H. Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Yvonne A. Maldonado, Dennis L. Murray, Walter A. Orenstein, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Shawn L. Ralston, Allan S. Lieberthal, H. Cody Meissner, Brian K. Alverson, Jill E. Baley, Anne M. Gadomski, David W. Johnson, Michael J. Light, Nizar F. Maraqa, Eneida A. Mendonca, Kieran J. Phelan, Joseph J. Zorc, Danette Stanko-Lopp & Sinsi Hernández-Cancio. (2014) Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 134:2, pages e620-e638.
Crossref
Crossref
Bernhard Resch. (2014) Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis. The Open Microbiology Journal 8:1, pages 71-77.
Crossref
Crossref
H. Cody Meissner & David W. Kimberlin. (2013) RSV Immunoprophylaxis: Does the Benefit Justify the Cost?. Pediatrics 132:5, pages 915-918.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evidence-Based Child Health: A Cochrane Review Journal 8:6, pages 2243-2376.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Marcello Lanari, Silvia Vandini, Santo Arcuri, Silvia Galletti & Giacomo Faldella. (2013) The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection. Clinical and Developmental Immunology 2013, pages 1-9.
Crossref
Crossref